Primary source: Medicines and Healthcare products Regulatory Agency (MHRA)
MHRA published a Class 4 defect notification for Mirtazapine 30mg Tablets (Cadila Pharmaceuticals).
Product quality defect may affect patient safety; requires batch checking and potential product recall actions.
Check for affected batches of Mirtazapine 30mg Tablets as described in EL(26)A/28 and implement any necessary quarantining or recall steps.
Regulatory Intelligence Lead
immediate
Healthcare professionals should check for the affected batches and note the defect as described in EL(26)A/28.
Check for affected batches of Mirtazapine 30mg Tablets as described in EL(26)A/28 and implement any necessary quarantining or recall steps.
MHRA issued a Class 4 Medicines Defect Notification for Mirtazapine 30mg Tablets (Cadila Pharmaceuticals Limited) on 8 June 2026. Healthcare professionals should identify affected batches and note the defect per EL(26)A/28.
What changed: MHRA published a Class 4 defect notification for Mirtazapine 30mg Tablets (Cadila Pharmaceuticals).
Why it matters: Product quality defect may affect patient safety; requires batch checking and potential product recall actions.
Practical implication: Check for affected batches of Mirtazapine 30mg Tablets as described in EL(26)A/28 and implement any necessary quarantining or recall steps.
Published from the Firecrawl agent regulatory extraction pipeline.
Implement a gap analysis for 505(b)(2) applications to identify safety data needs and adjust safety monitoring systems as necessary to accommodate new product characteristics.
MAHs and sponsors must enhance their pharmacovigilance systems to monitor microbiome-specific safety issues, comply with established safety standards, and address concerns related to antimicrobial resistance.
Stakeholders, including manufacturers and clinicians, must review and potentially revise their post-market vigilance and safety monitoring protocols in response to the FDA's proposed regulatory approaches for generative AI devices.
Developers of MBMPs must align their safety assessment protocols with the MHRA's expectations and are encouraged to engage with the MHRA early to establish appropriate regulatory strategies.
